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Abstract
Background: The number of new technologies for risk assessment available in health care is increasing. These
technologies are intended to contribute to both improved care practices and improved patient outcomes. To do so
however, there is a need to study how new technologies are understood and interpreted by users in clinical
practice. The objective of this study was to explore patient and physician perspectives on the usefulness of a new
technology to detect Cardiovascular Autonomic Neuropathy (CAN) in a specialist diabetes clinic. The technology is
a handheld device that measures resting heart rate and conducts three cardiac autonomic reflex tests to evaluate
heart rate variability.
Methods: The study relied on three sources of data: observations of medical consultations where results of the
CAN test were reported (n = 8); interviews with patients who had received the CAN test (n = 19); and interviews
with physicians who reported results of the CAN test (n = 9). Data were collected at the specialist diabetes clinic
between November 2013 and January 2014. Data were analysed using the concept of technological frames which
is used to assess how physicians and patients understand and interpret the new technology.
Results: Physicians generally found it difficult to communicate test results to patients in terms that patients could
understand and to translate results into meaningful implications for the treatment of patients. Results of the study
indicate that patients did not recall having done the CAN test nor recall receiving the results. Furthermore, patients
were generally unsure about the purpose of the CAN test and the implications of the results.
Discussion: Involving patients and physicians is essential when a new technology is introduced in clinical practice.
This particularly includes the interpretation and communication processes related to its use.
Conclusions: The integration of a new risk assessment technology into clinical practice can be accompanied by
several challenges. It is suggested that more information about the CAN test be provided to patients and that a
dialogue-based approach be used when communicating test results to patients in order to best support the use of
the technology in clinical practice.
Keywords: Users’ experiences, Technology, Risk assessment, Diabetes, Cardiac autonomic neuropathy
* Correspondence: riap@steno.dk
1Health Promotion Research, Steno Diabetes Center A/S, Gentofte, Denmark
Full list of author information is available at the end of the article
© 2015 Pals et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Pals et al. BMC Health Services Research  (2015) 15:402 
DOI 10.1186/s12913-015-1071-1
Background
In recent years the number of new healthcare technolo-
gies available to the healthcare industry has increased
rapidly. Most of these new technologies can be charac-
terized as decision support systems, often utilizing com-
puter applications that are intended to assist health
professionals and patients in making decisions about
care and intervention options [1, 2]. However, according
to Berg et al. [3] a major impediment to the introduction
of new technologies in health care practice is the need to
integrate new technologies into existing routines [3]. For
instance, the technology may seem illogical to the users if
the actions prescribed by the technology run against their
daily routines [4, 5]. This points to the importance of
studying how patients and physicians understand the new
technology in relation to their daily practice.
Studies of user perspectives on new healthcare tech-
nologies have shown that health professionals and pa-
tients may consider new technologies as useful tools
assisting health professionals and patients in clinical de-
cision making [2, 6, 7]. However, it has also been shown
that health professionals find it difficult to integrate
technology into their work practices if there is a mis-
match between the expectations of the technology and
work practices [8]. This can result in resistance to use
the technology, partial use of the technology or other
practices to overcome perceived limitations of the tech-
nology [8]. In addition, studies have shown that differing
priorities between health professionals and patients
translate into differing criteria when assessing the useful-
ness of new technology [2, 6, 7]. Two studies of user at-
titudes toward a new technology for cardiovascular risk
assessment found that the main concern of clinicians
was that the use of the system would increase consult-
ation time [2, 6]. In addition, clinicians reported some
difficulties using the technology. In a study by Wilson et
al. [2], patients found that the program positively im-
pacted the consultation process, allowing them to con-
tribute to the assessment and management of their
cardiovascular risk. However, other studies have found that
new technologies can interfere with health professional-
patient relationships, creating for example, a loss of rela-
tional contact [7, 9].
In considering the aforementioned studies it is import-
ant to note that new healthcare technologies vary con-
siderably in their design and function [1]. They differ
according to the task they are designed to support, the
way patient data are utilized, the types of outputs that
are generated and the ways outputs are communicated
to health professionals and patients [1]. In this study we
focus on a new technology designed to detect Cardiac
Autonomic Neuropathy (CAN) in people with diabetes.
CAN is a serious and frequently occurring complica-
tion of diabetes and has been reported to be a predictor
of cardiovascular morbidity and mortality in people with
diabetes [10]. It has been shown that CAN is associated
with a high risk of cardiac arrhythmias and sudden
death, which is possibly related to silent myocardial is-
chemia [11]. Abnormalities in cardiac autonomic activ-
ities can be found in people at diabetes onset and in
people with pre-diabetes [12, 13]. Patients are often un-
aware of having CAN, as the complication may be asymp-
tomatic even long into the course of diabetes [10, 12, 13].
It has been suggested that early detection of CAN is im-
portant to motivate patients and physicians to minimize
risk factors and thereby reduce further development of
complications [14, 15]. It is therefore currently recom-
mended that screening for CAN takes place at point of
diagnosis of type 2 diabetes and within five years after
diagnosis of type 1 diabetes, to best improve health out-
comes [16, 17].
CAN screening can be performed using a recently de-
veloped handheld device, the Vagus™ device [14]. The
device measures resting heart rate and conducts three
different standardized cardiac autonomic reflex tests to
evaluate heart rate variability [14]. The tests include
measurement of heart rate response during rest, after
changing position, during expiration and inspiration and
during Valsalva maneuver [14]. The measurement of
heart rate variability using cardiac autonomic reflex tests
is currently the most sensitive and specific test for CAN
[10]. Abnormal heart rate variability in one test indicates
early signs of CAN or borderline disease. Two or more
tests demonstrating abnormal heart rate variability con-
firm a diagnosis of CAN [14]. The prevalence of CAN in
people with diabetes was recently estimated using the
technology and use of the new technology was found to
be both feasible in and relevant to clinical practice [14].
The developers of the CAN screening device have de-
scribed three primary functions of the tool: 1) help refine
cardiovascular risk stratification, 2) lead to an increased
focus on the prevention of late complications of dia-
betes, and 3) serve as a tool to engage patients in their
own diabetes care1.
The functions described above suggest that the device
is intended to support health professionals in clinical de-
cision making and assist patients in their care through
detection of CAN Fig. 12. However, to transform these
intentions into practice, the intended use of the technol-
ogy must be supported by the users and the organizational
context of use. This requires that users learn how to
utilize the technology and start to actually use it in their
daily work [18]. Adoption of a new technology is therefore
a continuous process requiring the engagement and em-
powerment of end-users [1, 19, 20]. To understand
whether or not this happens and the process by which it
might occur, there is a need to examine how the technol-
ogy is perceived by physicians and patients in clinical
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practice and what meaning they ascribe to the technology
[21–23]. This includes the processes by which test results
are understood and communicated in clinical practice.
The objective of this study was to explore patient and
physician perspectives on the use of a new CAN detec-
tion technology at a Danish specialist diabetes clinic in
the greater Copenhagen area.
Theoretical framework
The study uses the concept of technological frames to
help assess how users understand and interpret the new
technology [24]. The concept of technological frames is
derived from social cognitive research but also draws on
sociological literature exploring the social constructions
of technology [24–26]. The notion of technological
frames is based on the premise that an individual’s inter-
pretation of new technology is fundamental in influen-
cing how he/she interacts with that technology [24]. An
individual’s technological frame is characterized by his
or her assumptions, expectations and prior knowledge
about a technology, reflecting the process of ‘making
sense’ of new technologies [18, 24]. According to Orli-
kowski and Gash [24] these sense-making processes
shape how new technology is used. Furthermore, the au-
thors suggest that different groups within an organization
develop different technological frames referring to incon-
gruences between frames. This implies that technological
frames are shared by members of a group having a par-
ticular interaction with the technology and reflect differ-
ent ways of knowing and making sense of technology.
However, frames can also be inconsistent within a group
[24]. The identification of those incongruences and incon-
sistences between and within user groups can provide an
explanation of the difficulties and unanticipated outcomes
associated with the introduction of a new technology in
an organization. In our study, the concept of technological
frames and the identification of incongruences and incon-
sistencies between and within frames informed the collec-
tion as well as the analysis and interpretation of data.
Methods
The exploration of patient and physician perspectives on
CAN test use in clinical practice was carried out be-
tween November 2013 and January 2014. The study is
based on three sources of data: observations of medical
consultations where results of the CAN test were
reported (n = 8); interviews with patients who had re-
ceived the CAN test (n = 19); and interviews with physi-
cians who reported results of the CAN test (n = 9).
Setting
Data collection was carried oData collection was carried
out at a specialist diabetes clinic in the greater
Copenhagen area parallel to a quantitativeut at a special-
ist diabetes clinic in the greater Copenhagen area paral-
lel to a quantitative implementation study of the Vagus™
device at the clinic. This study was initiated as a qualita-
tive contribution to the implementation study to explore
user perspectives on the introduction of the device to
the clinic within the period of November 2013 and Janu-
ary 2014. The clinic serves as an integrated part of the
Danish National Health Service and has a patient base of
around 5600 patients with type 1 and type 2 diabetes
from the Capital Region of Denmark. Physicians who
participated in the study were invited to attend a sem-
inar series over the course of four different mornings at
the specialist diabetes clinic. At the seminars, physicians
were introduced to CAN and CAN diagnosis. Further-
more, they were shown how to use the device (Vagus™)
to conduct a CAN test and were provided with an infor-
mation sheet outlining the characteristics of patients eli-
gible for the CAN test, diagnostic criteria for CAN and a
set of guidelines for using the CAN test in clinical prac-
tice. At the clinic, the CAN test was performed by la-
boratory technicians. Physicians could then access test
results through the Electronic Patient Record (EPR) and
use the result in medical consultations with patients. Pa-
tients eligible for the CAN test received an invitation let-
ter with information on the test.
Data collection
Patients who received the CAN test and where sched-
uled to receive the results at a subsequent medical con-
sultation between November 2013 and January 2014
were identified through the EPR (n = 55). A patient coord-
inator at the clinic assisted in identifying those patients.
We conducted observations between January 2nd and
January 14th 2014. At days where consultations were
scheduled, we contacted the respective physicians to re-
quest permission to perform observations. In addition, we
had correspondence with a nurse who kept us updated
about forthcoming consultations where test results were
Fig. 1 The intended use of the CAN test in clinical practice
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to be provided. A series of observation sessions of medical
consultations in which CAN test results were reported (n
= 8) were organized. However, in one observation it
turned out that the patient had not received the CAN test
due to complications.
Sampling
We (RASP, UMH, CBJ) used the following methods to
recruit patients and physicians for interviews. Physicians
were recruited through 1) personal approach following
observations of consultations, 2) e-mail invitations to all
physicians at the specialist diabetes clinic. Patients were
recruited through 1) personal approach following obser-
vations of consultations, 2) phone calls based on data
from the EPR Fig. 23.
After each observation session, the patient and phys-
ician were approached with a request to participate in
interviews. Using this method, we recruited three physi-
cians and seven patients for interviews.
In parallel with observations, we invited all physicians at
the specialist diabetes clinic (n = 31) by e-mail to participate
in interviews. None of the invited physicians responded to
the request and in a purposeful sampling process we re-
cruited eight physicians for a further follow-up invitation.
Selection was based on physicians’ level of clinical experi-
ence ensuring that both chief physicians and less experi-
enced physicians were invited. In addition, we selected
physicians assumed to have more consultations with pa-
tients and thus have more frequent communication of test
results. Of these eight physicians, six agreed to participate.
Combined with the three physicians recruited from obser-
vation sessions, interviews were conducted with nine physi-
cians in total. To recruit patients for interviews besides the
seven patients recruited at observations, we retrieved phone
numbers of patients identified through the EPR. We con-
tacted all patients identified through the EPR whose phone
numbers we were able to retrieve (n = 25) and conducted
an additional 12 phone interviews between January 14th
and January 31st 2014. The 13 remaining patients could not
be reached by phone. None of the patients refused to
participate.
Observation and interview guides
The primary focus of the observations was to study phy-
sicians’ use of the results of the CAN test in clinical
practice and to study the communication of test results.
At each observation session the observer (RASP, UMH,
CBJ) collected field notes based on an observation
guide. The observation guide addressed the amount
of time spent on communication of test results, the
explanations provided by physicians, the dialogue and
terminologies used in the communication of test re-
sults as well as patients’ reaction to the information
provided.
Fig. 2 Recruitment of participants for the study
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We (RASP, UMH, CBJ) used semi-structured interview
guides for interviews with physicians and patients. The
interview guides were based on the concept of techno-
logical frames focusing on assumptions, perceptions and
knowledge of the introduction of the CAN test. This in-
cluded implications for clinical practice and the commu-
nication of test results. Physicians, patients and the
interviewer were allowed to develop or introduce new
themes. The duration of each interview was about
30 min (mean: 22 min). Interviews were audio-taped and
transcribed.
Informed consent was obtained from physicians and
patients prior to observations of medical consultations
and conducting interviews. Written consent was ob-
tained for interviews in person and verbal consent for
phone interviews. The study was accepted by the
National Committee on Health Research Ethics and the
Danish Data Protection Agency.
Analytical approach
Patient and physician perspectives on the CAN test were
analysed qualitatively. All data including interviews and
field observations were analysed using content analysis
to systematically make inferences about the intentions
and interpretations of physicians and patients as de-
scribed by Agar [27] and Eisenhardt [28]. In the proced-
ure, we focused on identifying statements or actions
reflecting physicians’ and patients’ technological frames.
This includes perceptions and knowledge of the CAN
test in terms of its implications for clinical practice and
the communication of test results. The examination of
data was carried out in the following steps in accordance
with Orlikowski and Gash [24]: 1) separating the data
into statements and actions of physicians and patients
respectively, 2) sorting the data into categories suggested
by the data, 3) comparing categories generated by the
data of physicians and patients to identify common
themes, 4) recoding of data using the proposed themes.
Using this iterative approach we aimed to determine a
set of themes that constituted core domains of physi-
cians’ and patients’ technological frames. During the
analysis process we reflected on our pre-assumptions as
well as whether our presence affected the clinical
performance.
Results
A total of 19 patients were interviewed. Age of patients
ranged from 36 to 79 years (mean age: 64). Three pa-
tients were female, and 16 were male. 16 were diagnosed
with type 2 diabetes and three with type 1 diabetes. The
duration of disease among patients with type 2 diabetes
ranged from two to 35 years (mean duration of disease:
12 years). Among patients with type 1 diabetes, the
range of disease duration was four to 43 years (average
disease duration: 24 years). A total of nine physicians
were interviewed. Six physicians were female, and three
were male. Three were chief physicians and six were less
experienced physicians. Characteristics of the study
population are shown in Table 1.
Of the 19 patients interviewed, four patients did not
go through the CAN test due to e.g. physical disability,
two patients had not received their test result, one pa-
tient did not have the test result registered and eight pa-
tients did not remember whether they had received a
test result leaving four patients who could actually re-
member and relate to the CAN test.
Our findings emphasize that the usefulness of a new
technology in clinical practice depends on users’ percep-
tions on how it can be translated into their daily prac-
tice. In our analysis, three central concepts emerged: 1)
perceptions of the clinical relevance of the CAN test and
2) communication of complex test results and 3) motiv-
ation for behavioural change. The three central concepts
are closely interrelated in the sense that physicians’ per-
ceptions on the clinical relevance of the test affect the
communication of test results. Furthermore, the inter-
action between patients and physicians can influence
whether patients perceive test results as a means to
change behaviour. However, we find it useful to analytic-
ally distinguish between concepts to highlight relevant
differences between patients’ and physicians’ interpreta-
tions of the CAN test.
Perceptions on the clinical relevance of the CAN test
Physicians perceived the CAN test as appropriate for
cardiovascular risk stratification, as illustrated in the fol-
lowing excerpt:“…the good thing about it [CAN test] is
exactly that it screens them [patients without symptoms]
rather than we just consider them in cases where we
think of symptoms that the patient might have…or where
we are skilled enough to ask about it every time. It is not
everyone with gastroparesis or something alike who notice
it until it has gone very far” (physician 1). Additionally,
Table 1 Characteristics of the study participants
Patients with diabetes Number
Female/male 3/16
Age (mean) 36-79 years old
(64 years old)
Diabetes type 1/2 3/16
Years with diabetes (mean)
• Type 1 • 4–43 years (24 years)
• Type 2 • 2–35 years (12 years)
Physicians N
Female/male 6/3
Chief physicians/less experienced physicians 3/6
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physicians perceived it as a replacement for existing tests
to diagnose CAN in patients: “You could say that it [the
CAN test] is a smart way of having an overall package
rather than having [patients] to go through several differ-
ent examinations” (physician 2).
However, some physicians suggested that the CAN test
is only a clinically relevant tool if it is used to confirm
CAN in patients already suspected of having the condi-
tion – not a test to be performed indiscriminately as a
broad screening for CAN in people with diabetes. As
one physician noted:”It is clinically relevant if there are
clinical signs of it [CAN], then it [CAN test] is some sort
of confirmation. But to use it for everybody? My personal
opinion is that it should be used when relevant” (phys-
ician 3).
Most patients did not recall being tested for CAN or
receiving test results from their physician. They sug-
gested that it could be difficult to find information about
the test and to distinguish the CAN test from other tests
at the specialist diabetes clinic. Patients also felt that too
much information was provided at once when visiting the
specialist diabetes clinic and that the interval between
testing and receiving results was sometimes as long as five
months, which may have increased their “forgetfulness”.
Some patients remembered part of the process of tak-
ing the test but did not recall or know how the device
worked or the reason for being tested. One patient re-
ported the following misunderstanding:”I did not even
know that they tested my internal nervous system. That
was not mentioned. I got the impression that it had to do
with testing my lung function” (patient 1). Patients who
could recall the test indicated that they had difficulty un-
derstanding the purpose of the test, as illustrated in the
following excerpt: “It makes sense if you are told ‘you
have this and this condition and you can do this and
that’. It is no good that the doctor goes ‘you have this con-
dition and there is nothing you can do about it’. It does
not make any sense” (patient 2).
Communication of complex test results
Although physicians considered the test useful, some
physicians expressed communicating results from the
CAN test to patients to be a complicated task. They
found it difficult to explain the nature of CAN and espe-
cially the implications of a pathological or borderline test
result. One physician explained: “It is a test that is diffi-
cult to report because it simply can be difficult to explain
the patients about autonomic neuropathy. I spend rela-
tively long time talking about it” (physician 4).
Other physicians did not report experiencing difficulty
communicating CAN test results to patients. However,
they reported needing more time to communicate a
pathological test result than a non-pathological test re-
sult because the former would generate questions about
potential implications. One physician noted: “It is time
consuming and it is not the only time consuming proced-
ure here. So you might sometimes wonder how much
more they think can be squeezed into fifteen minutes”
(physician 5). Observations generally revealed that physi-
cians assessed and compared the value of using consult-
ation time to explain CAN test results with that of other
pressing issues.
Our observations showed that physicians communicated
test results in different ways. The process varied according
to physicians’ perceptions of patients’ need for informa-
tion, which affected the way test results were explained
and the amount of information provided on the physio-
logical basis of the test. As one physician noted: “The pa-
tients don’t care about stuff like heart rhythm variability I
guess. And maybe they don’t care about the long explica-
tion and just want to know that it looks fine. But I have
this idea of inviting them to a deeper talk about it to
understand what we are talking about” (physician 6).
Other physicians were particularly sensitive to termin-
ology choice when discussing results with patients as a
means of facilitating the highest level of understanding
in the patient: “I try to listen to the patient and see if he
or she understands what I say. Otherwise I must say
something that suits the patient. I try to use words that
are closely related to the professional terms that can be
understood” (physician 7). Nonetheless, some patients
still suggested that it could be challenging for physicians
to translate their professional understanding of test re-
sults into terms that would be meaningful and compre-
hensible to patients: “Things are self-evident and clear
when you are an expert in a field, and so it can be diffi-
cult to explain the patient why you measure something
specific and what that means (…) the physician has to be
very pedagogical” (patient 3). Our observations showed
that most physicians did not systematically investigate
whether patients understood their message, which indi-
cated a communication process characterized by a lack
of dialogue.
Some physicians did not want to create undue concern
in patients by communicating test results: “If a patient
has a pathological test, then it might worry the patient’-
will I collapse? Will I die?’ Because it is not something
we can really fix. You need to communicate in a way so
you don’t unduly cause concern but makes the test result
usable in a positive sense” (physician 2).
Overall, observations indicate that physicians found it
challenging to communicate test results to patients.
Additionally, they were cautious about discussing test
results if they felt they could not translate them into
meaningful and clearly defined course of action for patient
treatment. These results suggest that the technological
frames of physicians contrast the technology developer’s
intentions in using the tool for risk assessment and
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encouraging preventive behaviours in patients. The techno-
logical frame of physicians was clearly reflected in patients’
knowledge and interpretations of the CAN test.
Motivation for behaviour change
As illustrated in the following excerpt from an interview,
a common challenge articulated by physicians was the
difficulty experienced in translating CAN test results
into meaningful implications for patient treatment: “If
you inform people about such thing as autonomic neur-
opathy, then they will always like to know if there is
something we can do about it. And that is difficult in my
view” (physician 5). Some physicians however, believed
that results from the CAN test would motivate patients to
better manage their diabetes or would serve as an incen-
tive for taking medications or promote behaviour change.
As one physician explained: “If you have a patient with an
increased cardiovascular risk, then there is a clear commu-
nicative effect of telling [the patient] that we have per-
formed this test that clearly indicates that you need blood
pressure-lowering and cholesterol-lowering [medicine]. I
think that the patient will pay close attention then”
(physician 1). Another physician suggested that the test
could encourage decision-making surrounding treatment,
explaining: “It clearly motivates the patient and I to ad-
dress additional lifestyle changes. You [the physician] can
use the test result in relation to your own practice. You are
often in a situation where you doubt whether you should
initiate a new treatment or not (…) it is clear that it may
encourage a decision-making process” (physician 6).
These physicians attributed a clinical value to the test
in terms of using it to justify decisions about care and in
this case to serve as an incentive for changing behaviour
and medication plans of patients. However, none of the
patients indicated that the test results would motivate
them to change behaviour. A patient who received a
borderline test result reported the following: “The result
will not affect how I handle my diabetes at all; because it
was borderline; and there is always a statistical uncer-
tainty (…) I cannot respond to it when it is a threshold
value” (patient 3).
The potential of the CAN test to induce behaviour
change was also challenged by the finding that many pa-
tients experienced difficulty remembering whether or
not they had taken the test and in understanding the im-
plications of test results. Additionally, the meaning that
patients ascribed to the test was strongly influenced by
their communication with physicians about test results
and thus by physicians’ perceptions of the test. Patients
found it frustrating to receive a pathological or a border-
line test result if they were left with no clear instructions
about how to act on CAN diagnosis or with a diffuse
risk of something. One patient noted the following: “It
was odd that no more time was spent on explaining what
it [CAN] was and what you occasionally could use the
results for” (patient 4). Patients’ and physicians’ attitudes
toward the CAN test could therefore be a barrier to
using the CAN test as a form of motivation for self-
management as intended by the developers of the
technology. Most prominently, patients requested more
information about the test and the implications of it.
Discussion
The results of this study reveal that the majority of partici-
pating physicians perceived the CAN test as an appropri-
ate tool for cardiovascular risk stratification. Additionally,
physicians perceived the test as helpful in supporting deci-
sions about care. However, some physicians found the test
to be relevant only in instances where the patient already
exhibits symptoms of CAN. Furthermore, it was challen-
ging for physicians to communicate test results in terms
that were meaningful and comprehensible to patients.
Most patients did not recall being tested for CAN or re-
ceiving the test results from their physician. Those who
did recall receiving the test were unsure about the purpose
of the test and the implications of the results. These re-
sults reflect that physicians and patients had different
technological frames with regard to their understanding of
the vision behind the introduction of the CAN technology
(the clinical relevance of the CAN test) and their under-
standing of how to apply the technology into their daily
practice (the communication and interpretation of test re-
sults). In addition, we identified inconsistencies with re-
gard to the technological frame of physicians as physicians
had different perceptions on the clinical relevance of the
CAN test. If these differences between and within techno-
logical frames are not articulated, they may hamper the
implementation of the technology as was the case in this
study.
In accordance with our findings, other studies have
found that the use of a technology in clinical practice
can be challenged by the perceptions of health profes-
sionals [2, 6, 29]. Short et al. [29] studied perspectives of
general practitioners on the adoption of a computerized
risk assessment system in general practice and identified
several perception-based barriers to the use of the sys-
tem. In line with our findings, general practitioners
found it difficult to communicate the output of the risk
assessment to patients. Furthermore, the general practi-
tioners expressed concern about explaining risk to pa-
tients and reported that the system required extra time
in consultations.
In other studies, technologies for risk assessment have
received more positive feedback from patients and general
practitioners, which proved to enhance the acceptance
and use of those technologies in clinical practice [2, 6].
For instance, Carroll et al. [6] involved clinicians and pa-
tients in designing and evaluating a decision support
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system that deals with cardiovascular risk prevention in
people with type 2 diabetes [6]. Clinicians and patients
were enthusiastic about the system and felt confident
using it after short training periods. However, in accord-
ance with the findings of our study, some patients had dif-
ficulties in interpreting the clinical results [6].
Gillespie [30] studied how risk was experienced by
people who were designated as being at risk of either
coronary heart disease or prostate cancer. One of his
main findings was that uncertainty was a fundamental
aspect of the experience of risk. Respondents were not
sure how to react to being at risk, were unsure of the
implications being at risk had for their everyday lives
and were not given clear instructions on how to address
their risk status [30]. These findings have been corrobo-
rated in other studies [31, 32]. Gillespie [30] argues that
the uncertainty led to patient fear, anxiety and uneasi-
ness about the future and that respondents were unable
to rely on self-monitoring of health through physical
symptoms. These observations support our finding that
the perceived uncertainty about the implications of the
CAN test could be a barrier to using the CAN test as a
motivation for self-management. However, given the sig-
nificant lack of recall in patients receiving the test result,
the CAN test did not seem to produce fear or anxiety,
but rather a request for more information on the test
and the meaning of results.
Our findings also indicate that physicians’ and patients’
attitudes varied widely with respect to the perceived im-
portance and implications of the CAN test. This both
concerned perceptions within the group of physicians
and between patients and physicians. Other studies have
identified different perceptions among physicians of the
use and value of technologies for risk assessment in
health care practice [2, 33]. For instance, some physi-
cians preferred to use their own questions rather than
questionnaires [2]. In addition, wide variations in physi-
cians’ interpretation of risk have been demonstrated
[33]. This can in turn affect how physicians communi-
cate risk to patients and patients’ understanding of risk,
which is also reflected in our study.
Discrepancies between patients’ and physicians’ per-
ceptions of clinical phenomena have also been docu-
mented elsewhere [34–36]. It has been shown that
health professionals value the quality of their own infor-
mation more positively than patients and that health
professionals to a higher degree than patients experience
that specific information was delivered to patients [35]
Additionally, a study on patients’ and health profes-
sionals’ ability to recall information provided in consul-
tations revealed that patients were unable to call to
mind even half of the topics discussed and could recall
even fewer decisions that were made about their treat-
ment than did health professionals [36]. According to
the authors, this lack of agreement could be related to
health professionals bringing their own agendas into the
consultation. However, it is also likely that the “forgetful-
ness” of patients in our study was influenced by other
factors. Possible factors include organizational issues in
terms of patients being overloaded with information
during their visits at the specialist diabetes clinic as well
as the knowledge, personal experiences, age and educa-
tional level of patients [37].
Practice implications
The findings of our study point to the importance of ac-
knowledging user perceptions of a technology before and
during the process of implementation. The identification
and discussion of technological frames of different user
groups may reduce the likelihood of misunderstandings
and difficulties around the use of new technologies. With
regard to this study, it is likely that the identified barriers
could have been articulated and discussed at an earlier
point in time if patients and physicians were consulted be-
fore the CAN technology was introduced to the specialist
diabetes clinic. This could imply the development of
guidelines around the communication about the CAN test
in clinical practice.
In response to the barriers that physicians and patients
perceive in relation to the use of the CAN test in clinical
practice, the findings of this study suggest that commu-
nication and information about the CAN test could be
improved. Improvements could be achieved through the
development of guidelines about a dialogue-based ap-
proach to the communication of test results which could
prove useful on how to provide clear and consistent in-
formation about the test. The communication between
patients and physicians about the CAN test could thus
be enhanced through dialogue targeting patient experi-
ences of the test and prompting patients to express their
thoughts and expectations. This includes the develop-
ment of health professionals’ communication skills e.g.
skills to include patients in clinical decision making and
encourage patient autonomy [36]. It has been shown
that patient autonomy is associated with increased mo-
tivation, better self-care and metabolic control in pa-
tients [38]. This suggests a need to develop physicians’
skills to encourage patient autonomy with regard to the
CAN test. In this study, we did not look into specific be-
haviours or skills that could serve this purpose, but a
number of related issues have been discussed in the lit-
erature. This includes skills to facilitate a person-centred
approach to communication e.g. asking patients about
their concerns, expectations and perceptions of the
problem in relation to their functioning.
An example of such an approach to the use of a tech-
nology for cardiovascular risk assessment is described
by Wilson et al. [2]. The technology builds on sharing
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management and partnership between patients and physi-
cians as well as the promotion of healthy lifestyles. Key
features include goal setting, written management plans
and regular follow-up. These features could inform use of
the CAN test in clinical practice at the specialist diabetes
clinic. For instance, physicians can support patients with a
pathological or borderline test result by collaborating with
them to develop an action plan, which can allow them to
feel a sense of control over their disease. In case of a non-
pathological test result physicians could invite patients to
enter into discussion about their current diabetes-related
behaviour and how to maintain or improve it. Physicians
must tailor the amount of information they provide to the
patient’s response. In addition, a vocabulary of common
terminologies applied to the invitation letter for the
test, the testing process, and communicating results is
suggested so that clear and consistent information is
available to patients.
On an organizational level, assessing available resources
and competencies and existing priorities of the intended
users of the technology can promote and improve the use
of the technology in clinical practice. In this case that in-
cludes the provision of training for improving communi-
cation about the CAN test in medical consultations
considering the short time frame of medical consultations.
Thus, the potential of the suggestions for improving the
translation of the technology into clinical practice can
only be realized in collaboration with the users in the spe-
cific context of use.
Limitations
Inclusion of more individuals who tested positive for CAN
could have enhanced our insights about this group of pa-
tients. However, there were surprisingly many patients who
did not recall the test and therefore were not able to elab-
orate on their experiences with the CAN test. It is also
likely that the physicians included in the study represent a
selected group due to the recruitment process where only
few of the invited physicians participated. With regard to
the analysis, the three central concepts identified are much
intertwined and thus difficult to distinguish from one
another in terms of defining what constitutes the techno-
logical frames of patients and physicians respectively. Fur-
thermore, we did not compare the technology with other
well-known technologies used for a longer period of time
in the clinic.
Conclusions
This study emphasizes the importance of investigating
patients’ and physicians’ understanding of a new tech-
nology when it is implemented in clinical practice. The
findings reveal that physicians found it challenging to
communicate the meaning of test results to patients
and to translate results into meaningful implications for
patient treatment. Patients were generally unsure about
the meaning of test results and did not indicate that test
results would motivate them to change behaviour. In
order to support the use of the technology in clinical prac-
tice, it is suggested that a dialogue-based approach be used
when communicating test results to patients including
gaining impression of the patient’s understanding of the
purpose of the CAN technology. In addition, it is sug-
gested that more information about the CAN test should
be provided to patients.
Endnotes
1These visions are described in a presentation by the
person responsible for implementing the technology at
the specialist diabetes clinic and were presented at set-
tings within and external to the clinic.
2Fig. 1 illustrates the anticipated use of the technology
at the specialist diabetes clinic.
3Fig. 2 illustrates the recruitment of participants for
the study.
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